177Lu-DOTA-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTA-D-Phe1-Tyr3-Thr8-octreotide, DOTATATE)、177Lu-前列腺特异膜抗原(prostate specific membrane antigen, PSMA)-617等核素治疗药物在临床中的成功应用为HER2阳性肿瘤的治疗提供...
Conclusion: Overall the described combination of HPLC and TLC provides a reliable tool for quality control of [177Lu]Lu-PSMA I&T. Keywords: PSMA, [177Lu]Lu-PSMA I&T, Zadavotide guraxetan, Radionuclide therapy, Quality control, HPLC, TLC, Validation Introduction Targeting the ...
In recent years, theranostics has become a promising approach for treating metastatic castration-resistant prostate cancer (mCRPC), with trials investigating targeted radioligand therapy, particularly using prostate-specific membrane antigen labeled with lutetium-177 ([177Lu]Lu-PSMA). The proper position ...
177Lu-DOTA-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTA-D-Phe1-Tyr3-Thr8-octreotide, DOTATATE)、177Lu-前列腺特异膜抗原(prostate specific membrane antigen, PSMA)-617等核素治疗药物在临床中的成功应用为HER2阳性肿瘤的治疗提供新的思路。HER2在肿瘤组织中高表达而在正常组织中低或不表达,这为HER2靶向放射性...
177治疗性放射性药物作为前列腺特异性膜抗原抑制剂(iPSMA),其中与杂环肼基烟酰胺(HYNIC)结合的1,4,7,10‑四氮杂环十二烷‑N,N,N”,N””‑四乙酸(DOTA)生成使构象异构体和分子内氢键的数量最小化的刚性化学结构,从而产生分子中的活性位点(Lys(Nal)‑NH‑CO‑NH‑Glu)对于PSMA蛋白的生物识别有...
Figure 2. Overall Survival Hazard Ratios for Estimands of Interest View LargeDownload HR indicates hazard ratio; IPCW, inverse probability of censoring weights; Lu-177, lutetium Lu 177 vipivotide tetraxetan; PSMA, prostate-specific membrane antigen; RPSFTM, rank-preserving structural failure ...
PSMAradioligand therapytumor markersBackground: Currently, prostate-specific membrane antigen-radioligand therapy (PSMA-RLT) is considered a last-line treatment option in advanced castration-resistant prostate cancer. Despite these patients' poor prognosis, accurate estimation of their overall survival (OS)...
radioligand therapy;α1-microglobulin;[99mTc]Tc-MAG3 imaging;[177Lu]Lu-PSMA-617;prostate cancer;mouse model;kidney damage;dosimetry Graphical Abstract 1. Introduction Prostate cancer (PCa) is among the most common malignancies in men. Initially all PCa tumors are androgen responsive and thus androge...
Mutations in DNA damage repair pathway genes, including BRCA2 and CHEK2 have also been reported in pancreatic NET48 and may promote tumour sensitivity to LuTate, as reported in BRCA2 mutant prostate cancer treated with Lu-177 PSMA therapy49. Using a robust tumour model endogenously expressing ...
Figure 2. Overall Survival Hazard Ratios for Estimands of Interest View LargeDownload HR indicates hazard ratio; IPCW, inverse probability of censoring weights; Lu-177, lutetium Lu 177 vipivotide tetraxetan; PSMA, prostate-specific membrane antigen; RPSFTM, rank-preserving structural failure ...